CHICAGO — Stereotactic body radiation therapy (SBRT) directed at progressive lesions in patients with oligoprogressive metastatic non-small cell lung cancer (NSCLC) was beneficial and significantly ...
Stereotactic body radiation therapy (SBRT) and surgery offer nearly equal overall survival rates for patients with stage I and II non–small cell lung cancer (NSCLC), according to population-based ...
Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...
Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to ...
Please provide your email address to receive an email when new articles are posted on . The addition of neoadjuvant durvalumab to stereotactic body radiotherapy appeared safe and conferred a nearly 55 ...
Role of PET scan in predicting response to neoadjuvant chemotherapy and long-term outcomes for stage II lung cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract ...
Cooperative antitumor activity between the retinoid X receptor (RXR)-selective agonist bexarotene and EGFR-tyrosine kinase inhibitors in preclinical models of NSCLC No significant financial ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback